QSAM completes enrollment of initial cohort in Phase 1 study of CycloSam

QSAM Biosciences announces the completion of enrollment in the first participant grouping of its Phase 1 study evaluating CycloSam in the treatment of bone cancer. The last participant dosed was a breast cancer patient with active metastatic bone cancer. QSAM‘s study is a multiple center, open label, dose escalation clinical trial intended to determine the maximum tolerated dose of CycloSam in patients, and also assess early safety and efficacy signals. The completed cohort of three participants received the lowest dosage of CycloSam in the study. The total dosage of the active radioisotope Samarium-153 to be received by the second cohort, expected to commence in early Q2 2023, will be 50% higher. The most recent participant in QSAM’s clinical trial was a patient with breast cancer that had metastasized to the bone, a serious and life-threatening disease for which there is an unmet need by patients and an area of high interest by management for the clinical trials and product development of CycloSam.